Detalhe da pesquisa
1.
Identification, structural, and biophysical characterization of a positive modulator of human Kv3.1 channels.
Proc Natl Acad Sci U S A
; 120(42): e2220029120, 2023 10 17.
Artigo
Inglês
| MEDLINE | ID: mdl-37812700
2.
Autonomic Dysfunction Linked to Inhibition of the Nav1.7 Sodium Channel.
Circulation
; 149(17): 1394-1396, 2024 Apr 23.
Artigo
Inglês
| MEDLINE | ID: mdl-38648272
3.
Benzoxazolinone aryl sulfonamides as potent, selective Nav1.7 inhibitors with in vivo efficacy in a preclinical pain model.
Bioorg Med Chem Lett
; 27(12): 2683-2688, 2017 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-28465103
4.
Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice.
Bioorg Med Chem Lett
; 27(10): 2087-2093, 2017 05 15.
Artigo
Inglês
| MEDLINE | ID: mdl-28389149
5.
Association of respiratory failure with inhibition of NaV1.6 in the phrenic nerve.
Channels (Austin)
; 16(1): 230-243, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36239534
6.
Guiding Chemically Synthesized Peptide Drug Lead Optimization by Derisking Mast Cell Degranulation-Related Toxicities of a NaV1.7 Peptide Inhibitor.
Toxicol Sci
; 185(2): 170-183, 2022 01 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34897513
7.
Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Nav1.7 for the Treatment of Pain.
J Med Chem
; 65(1): 485-496, 2022 01 13.
Artigo
Inglês
| MEDLINE | ID: mdl-34931831
8.
Pyridyl amides as potent inhibitors of T-type calcium channels.
Bioorg Med Chem Lett
; 21(6): 1692-6, 2011 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-21316226
9.
Translational Pharmacokinetic-Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose.
Front Pharmacol
; 12: 786078, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-35002718
10.
Discovery of Arylsulfonamide Nav1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity Profile.
ACS Med Chem Lett
; 12(6): 1038-1049, 2021 Jun 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34141090
11.
Nav1.7 target modulation and efficacy can be measured in nonhuman primate assays.
Sci Transl Med
; 13(594)2021 05 19.
Artigo
Inglês
| MEDLINE | ID: mdl-34011626
12.
In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice.
J Pharmacol Exp Ther
; 335(2): 409-17, 2010 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-20682849
13.
Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists.
Bioorg Med Chem Lett
; 20(17): 5147-52, 2010 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-20673719
14.
Inhibition of sodium channel gating by trapping the domain II voltage sensor with protoxin II.
Mol Pharmacol
; 73(3): 1020-8, 2008 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-18156314
15.
Trazodone inhibits T-type calcium channels.
Neuropharmacology
; 53(2): 308-17, 2007 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-17610910
16.
Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications.
J Med Chem
; 58(18): 7093-118, 2015 Sep 24.
Artigo
Inglês
| MEDLINE | ID: mdl-25927480
17.
Discovery of a pharmacologically active antagonist of the two-pore-domain potassium channel K2P9.1 (TASK-3).
ChemMedChem
; 7(1): 123-33, 2012 Jan 02.
Artigo
Inglês
| MEDLINE | ID: mdl-21916012
18.
TASK-3 as a potential antidepressant target.
Brain Res
; 1416: 69-79, 2011 Oct 06.
Artigo
Inglês
| MEDLINE | ID: mdl-21885038
19.
Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists.
ACS Med Chem Lett
; 1(2): 75-9, 2010 May 13.
Artigo
Inglês
| MEDLINE | ID: mdl-24900180
20.
Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents.
ACS Med Chem Lett
; 1(9): 504-9, 2010 Dec 09.
Artigo
Inglês
| MEDLINE | ID: mdl-24900239